Efficacy and Safety of Dapagliflozin-Vildagliptin in Indian T2DM Patients with CV Risk Factors
Written By : Anshika Mishra
Published On 2026-01-30 07:28 GMT | Update On 2026-01-30 08:45 GMT
Advertisement
The Fixed-Dose Combination (FDC) of Dapagliflozin 5 mg + Vildagliptin 50 mg demonstrated significant improvements in Glycemic Control, Metabolic parameters, and a favorable safety profile in Indian patients with Type 2 Diabetes Mellitus (T2DM) and Cardiovascular Risk Factors, according to a recent study published in the November 2025 issue of Cureus.
This retrospective, single-center study evaluated 101 T2DM patients prescribed the Dapagliflozin –Vildagliptin FDC over a three-month period. Of these, 49 patients completed the follow-up and were included in the final analysis. Patients were on existing antidiabetic therapy, with the FDC added as an add-on treatment.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.